Reducing Birth Defects from Isotretinoin
Author Information
Author(s): Lorien Abroms, Edward Maibach, Katherine Lyon-Daniel, Steven R. Feldman
Primary Institution: George Washington University; Centers for Disease Control and Prevention; Wake Forest University School of Medicine
Hypothesis
Will iPLEDGE, the recently implemented US risk reduction program, reduce isotretinoin birth defects, or is it an unproven and overly burdensome system?
Conclusion
The iPLEDGE program has potential benefits but has not been formally evaluated to determine its effectiveness in reducing isotretinoin-exposed pregnancies.
Supporting Evidence
- Isotretinoin is effective for severe acne but is highly teratogenic.
- Over 1.4 million isotretinoin prescriptions are dispensed annually in the US.
- Previous risk management programs have not sufficiently reduced the number of exposed pregnancies.
Takeaway
Isotretinoin helps treat severe acne but can cause birth defects, so a program called iPLEDGE was created to help prevent this, although it has some issues.
Methodology
The article discusses the history and analysis of risk management programs for isotretinoin, focusing on the iPLEDGE program.
Potential Biases
Concerns exist regarding the potential for insufficient counseling and motivation among patients, particularly teenagers.
Limitations
The iPLEDGE program has not been formally evaluated, and there are concerns about its complexity and user compliance.
Participant Demographics
About half of isotretinoin prescriptions are given to females, most of whom are in their reproductive years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website